The KIF17 antibody is a research tool designed to detect and study Kinesin Family Member 17 (KIF17), a motor protein belonging to the kinesin-2 subfamily. KIF17 plays a critical role in intracellular transport, particularly in neurons, where it facilitates the anterograde movement of cargo along microtubules. It is best known for transporting vesicles containing the NR2B subunit of NMDA (N-methyl-D-aspartate) receptors in dendrites, contributing to synaptic plasticity, learning, and memory. Structurally, KIF17 contains a conserved kinesin motor domain that binds ATP and microtubules, enabling mechanical movement, and a tail domain that interacts with specific cargo adaptors. Dysregulation of KIF17 has been implicated in neurological disorders, including Alzheimer’s disease, schizophrenia, and neurodevelopmental conditions. Researchers use KIF17 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate its expression, localization, and functional interactions in cellular and animal models. These antibodies are essential for elucidating KIF17’s role in neuronal health, disease mechanisms, and potential therapeutic targets. Validation of antibody specificity, often through knockout controls or siRNA knockdown, is crucial to ensure reliable experimental outcomes. Commercial KIF17 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes within the protein.